News articles about Apollo Endosurgery (NASDAQ:APEN) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.7689399707746 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of research analysts have commented on APEN shares. Zacks Investment Research cut Apollo Endosurgery from a “hold” rating to a “sell” rating in a research note on Tuesday, March 6th. Roth Capital set a $10.00 price objective on Apollo Endosurgery and gave the stock a “buy” rating in a research note on Thursday, January 4th. Northland Securities restated a “buy” rating and set a $12.00 price objective on shares of Apollo Endosurgery in a research note on Thursday, February 8th. Finally, ValuEngine upgraded Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the company. Apollo Endosurgery has an average rating of “Hold” and a consensus price target of $9.44.
Apollo Endosurgery (APEN) traded down $0.02 during trading hours on Friday, hitting $6.14. The company had a trading volume of 39,773 shares, compared to its average volume of 18,587. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.68 and a current ratio of 2.23. Apollo Endosurgery has a fifty-two week low of $3.55 and a fifty-two week high of $14.09. The firm has a market capitalization of $106.52, a PE ratio of -2.86 and a beta of 0.46.
In other Apollo Endosurgery news, major shareholder Stonepine Capital, L.P. purchased 185,157 shares of the business’s stock in a transaction that occurred on Friday, December 22nd. The shares were acquired at an average price of $4.85 per share, for a total transaction of $898,011.45. Following the completion of the purchase, the insider now owns 2,410,141 shares in the company, valued at approximately $11,689,183.85. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Matthew S. Crawford purchased 4,038 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The stock was acquired at an average price of $6.20 per share, for a total transaction of $25,035.60. Following the purchase, the director now owns 53,715 shares of the company’s stock, valued at approximately $333,033. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 267,924 shares of company stock worth $1,313,086. Insiders own 74.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was posted by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/17/apollo-endosurgery-apen-earning-somewhat-favorable-news-coverage-report-finds/1999589.html.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.